• Explore /
  • Poster
  • / First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).

First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).

Abstract Poster

Authors

MARIA ALSINA

Maria Alsina

Vall d'Hebron University Hospital, Barcelona, Spain

Maria Alsina , Valentina Boni , Jan H.M. Schellens , Victor Moreno , Kees Bol , Martine Westendorp , L. Andres Sirulnik , Josep Tabernero , Emiliano Calvo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Antibodies

Clinical Trial Registration Number

NCT02912949

Citation

J Clin Oncol 35, 2017 (suppl; abstr 2522)

DOI

10.1200/JCO.2017.35.15_suppl.2522

Abstract #

2522

Poster Bd #

14

Abstract Disclosures

Similar Posters

First Author: D. Gajria

First Author: Erika Paige Hamilton

First Author: Stephen K. L. Chia

First Author: Beatrice Bachmeier